irritable bowel syndrome | Ricerc@Sapienza

Tumor necrosis factor-α and solute carrier family 22 member 4 gene polymorphisms as potential determinants of intestinal dysbiosis

ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 1. Initial diagnosis, monitoring of known IBD, detections of complications

This new diagnostic consensus guideline is a joint project of the European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] that now merges the former ECCO-ESGAR Imaging Guideline and the former ECCO Endoscopy
Guideline, also including laboratory parameters. It has been drafted by 30 ECCO and ESGAR members from 17 European countries. All the authors recognize th e work of and are grateful to previous ECCO and ESGAR members who contributed tocreating the earlier consensus guidelines on

Tegaserod for the treatment of Irritable Bowel syndrome

Tegaserod (Zelnorm®) is a 5-hydroxytryptamine (serotonin) type 4 receptor agonist for the treatment of hypomotility disorders of the lower gastrointestinal tract associated with the irritable bowel syndrome with constipation (IBS-C).